<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="982">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01832350</url>
  </required_header>
  <id_info>
    <org_study_id>AVP923</org_study_id>
    <nct_id>NCT01832350</nct_id>
  </id_info>
  <brief_title>Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease</brief_title>
  <official_title>Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Hospital and Medical Center, Phoenix</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avanir Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Joseph's Hospital and Medical Center, Phoenix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test the hypothesis that Nuedexta (20/10)&#xD;
      administered orally will reduce Pseudobulbar Affect (PBA) frequency and severity&#xD;
      (CNS-Lability Scale and PLACS), with satisfactory safety and high tolerability in patients&#xD;
      with Alzheimer's Disease (AD). The primary objective will be evaluated using a study endpoint&#xD;
      at 1, 13, 26 weeks after initiation of treatment. The secondary objective of this study is to&#xD;
      evaluate the benefit of treatment with Nuedexta (20/10) on cognition and functionality as&#xD;
      demonstrated in the Rey Auditory Verbal Learning Test (RAVLT), Trail making A and B, Wechsler&#xD;
      Memory Scale (WMS) logical memory and delayed recall, Controlled Oral Word Association&#xD;
      (COWA), Clinical Dementia Rating (CDR), Neuropsychiatric Inventory (NPI), Alzheimer's Disease&#xD;
      Cooperative Study Activities of Daily Living Inventory (ADCSADL) and the 11-item Alzheimer's&#xD;
      Disease Assessment Scale-Cognitive subscore (ADAS-Cog11).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decided to stop study early&#xD;
  </why_stopped>
  <start_date type="Actual">August 28, 2012</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">December 1, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of PBA frequency</measure>
    <time_frame>1, 13, and 26 weeks after initiation of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of PBA severity</measure>
    <time_frame>1, 13, and 26 weeks after initiation of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Pseudobulbar Affect (PBA)</condition>
  <arm_group>
    <arm_group_label>Nuedexta (20/10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nuedexta (20/10)</intervention_name>
    <description>Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.</description>
    <arm_group_label>Nuedexta (20/10)</arm_group_label>
    <other_name>Dextromethorphan/Quinidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/female 55 to 90 years, inclusive.&#xD;
&#xD;
          -  Meets National Institute of Neurological and Communicative Disorders and&#xD;
             Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable AD.&#xD;
&#xD;
          -  Modified Hachinski Ischemia Scale score of ≤4.&#xD;
&#xD;
          -  Folstein Mini Mental State Exam score 16-26 at Visit 1.&#xD;
&#xD;
          -  Geriatric Depression Scale score ≤6. For patient with history of depression, he/she&#xD;
             have been on steady dose of anti-depressant for at least 3 months.&#xD;
&#xD;
          -  Clinical history and relevant symptoms of Pseudobulbar Affect.&#xD;
&#xD;
          -  Center for Neurologic Study-Lability Scale score at baseline ≥13.&#xD;
&#xD;
          -  Stable hematologic, hepatic, and renal function, with no clinically significant&#xD;
             symptoms, and with clinical laboratory results (CBC, clinical chemistry, and&#xD;
             urinalysis) up to 1-fold higher than upper limit of normal range.&#xD;
&#xD;
          -  Resting respiratory rate 12-20/minute.&#xD;
&#xD;
          -  MRI or CT scan within past 12 months; no findings inconsistent with diagnosis of AD.&#xD;
&#xD;
          -  ECG (within 4 weeks prior to entry)with no evidence of clinically significant&#xD;
             abnormalities.&#xD;
&#xD;
          -  Concurrent treatment with an acetylcholinesterase inhibitor or memantine allowed; must&#xD;
             be on stable dose at least 2 months before screening. Dosing must remain stable&#xD;
             throughout the study.&#xD;
&#xD;
          -  Use of SSRI's allowed. Must have used for 3 months prior to study entry; dose must&#xD;
             remain unchanged during course of study.&#xD;
&#xD;
          -  No current symptoms of depressive disorder.&#xD;
&#xD;
          -  Score of 19 or lower in the Beck Depression Inventory.&#xD;
&#xD;
          -  Agrees to use no prohibited medications during study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has current serious or unstable illnesses that, in investigator's opinion, could&#xD;
             interfere with analysis of safety and efficacy data; has life expectancy &lt;2 years.&#xD;
&#xD;
          -  No reliable caregiver in frequent contact with patient (at least 10 hours/week.&#xD;
&#xD;
          -  Current or prior history of major psychiatric disturbance.&#xD;
&#xD;
          -  Have been in other clinical study within 30 days of entry.&#xD;
&#xD;
          -  Score of 20 or higher in Beck Depression Inventory.&#xD;
&#xD;
          -  Multiple episodes of head trauma, history within last year of serious infectious&#xD;
             disease affecting the brain, head trauma resulting in protracted loss of&#xD;
             consciousness, or myasthenia gravis.&#xD;
&#xD;
          -  Within the last 5 years, history of a primary or recurrent malignant disease.&#xD;
&#xD;
          -  Known sensitivity to quinidine or dextromethorphan.&#xD;
&#xD;
          -  History of human immunodeficiency virus, multiple or severe drug allergies, or severe&#xD;
             post-treatment hypersensitivity reactions.&#xD;
&#xD;
          -  History of chronic alcohol or drug abuse/dependence within the past 5 years.&#xD;
&#xD;
          -  Judged by investigator to be at serious risk for suicide.&#xD;
&#xD;
          -  Has a recent or current lab result indicating clinically significant lab abnormality.&#xD;
&#xD;
          -  At Visit 1 has ALT/SGPT values ≥2 times upper limit of normal (ULN); AST/SGOT values&#xD;
             ≥3 times the ULN; total bilirubin values ≥2 times the ULN.&#xD;
&#xD;
          -  Resting diurnal oxygen saturation &lt;95%.&#xD;
&#xD;
          -  Received dextromethorphan and quinidine within previous 6 months.&#xD;
&#xD;
          -  Hypotension (systolic BP &lt;100 mm Hg); postural syncope; unexplained syncope.&#xD;
&#xD;
          -  Used medications that affect the CNS (except for AD) for less than 4 weeks.&#xD;
&#xD;
          -  On disallowed concomitant medications.&#xD;
&#xD;
          -  Experiencing acute exacerbation of underlying neurological disorder within previous 2&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong Shi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix AZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci. 2005 Fall;17(4):447-54. Review.</citation>
    <PMID>16387982</PMID>
  </reference>
  <reference>
    <citation>Green RL. Regulation of Affect. Semin Clin Neuropsychiatry. 1998 Jul;3(3):195-200.</citation>
    <PMID>10085207</PMID>
  </reference>
  <reference>
    <citation>Lieberman A, Benson DF. Control of emotional expression in pseudobulbar palsy. A personal experience. Arch Neurol. 1977 Nov;34(11):717-9.</citation>
    <PMID>911237</PMID>
  </reference>
  <reference>
    <citation>Starkstein SE, Migliorelli R, Tesón A, Petracca G, Chemerinsky E, Manes F, Leiguarda R. Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):55-60.</citation>
    <PMID>7608711</PMID>
  </reference>
  <reference>
    <citation>Tanaka M, Sumitsuji N. Electromyographic study of facial expressions during pathological laughing and crying. Electromyogr Clin Neurophysiol. 1991 Oct-Nov;31(7):399-406.</citation>
    <PMID>1748077</PMID>
  </reference>
  <reference>
    <citation>Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R; Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010 Nov;68(5):693-702. doi: 10.1002/ana.22093.</citation>
    <PMID>20839238</PMID>
  </reference>
  <reference>
    <citation>Strowd RE, Cartwright MS, Okun MS, Haq I, Siddiqui MS. Pseudobulbar affect: prevalence and quality of life impact in movement disorders. J Neurol. 2010 Aug;257(8):1382-7. doi: 10.1007/s00415-010-5550-3. Epub 2010 Apr 8.</citation>
    <PMID>20376475</PMID>
  </reference>
  <reference>
    <citation>Wolf JK, Santana HB, Thorpy M. Treatment of &quot;emotional incontinence&quot; with levodopa. Neurology. 1979 Oct;29(10):1435-6.</citation>
    <PMID>573397</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 9, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quinidine</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

